Literature DB >> 16883071

Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin.

Xamila Salcedo-Mora1, José Maté, Jesus Medina, Syong J Nam Cha, Javier P Gisbert, Ricardo Moreno-Otero.   

Abstract

We describe the case of a patient with a diagnosis of Crohn's disease and accidental infection during abdominal surgery by hepatitis C virus (HCV) who received combination therapy with pegylated interferon-alpha2b (1.5 microg/kg weekly) plus ribavirin (10.6 mg/kg daily) for histologically demonstrated chronic hepatitis C. After 48 weeks treatment, serum transaminase levels were normal and viremia (HCV RNA) was negative (end-of-treatment response); 24 weeks later (follow-up period), a sustained virological response was demonstrated. The tolerance to combination antiviral therapy was good, without intestinal symptoms of inflammatory bowel disease recurrence. We conclude that current antiviral therapies with immunomodulatory effects may be helpful and safe for patients with inflammatory bowel disease infected by hepatitis C virus. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16883071     DOI: 10.1159/000094787

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

Review 1.  Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Authors:  María Rojas-Feria; Manuel Castro; Emilio Suárez; Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 2.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

3.  Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.

Authors:  Alina M Allen; W Ray Kim; Joseph Larson; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

4.  Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia.

Authors:  Eun Soo Kim
Journal:  Intest Res       Date:  2017-01-31

5.  Network-based study reveals potential infection pathways of hepatitis-C leading to various diseases.

Authors:  Anirban Mukhopadhyay; Ujjwal Maulik
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.